The Technical Analyst
BioXcel Therapeutics Inc [BTAI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BioXcel Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
7.84% $2.75
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 92.49 mill |
| EPS: | -6.15 |
| P/E: | -0.450 |
| Earnings Date: | May 05, 2024 |
| SharesOutstanding: | 33.63 mill |
| Avg Daily Volume: | 1.535 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.450 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -0.450 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.061 (-138.60%) $-3.81 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.51 - 2.99 ( +/- 8.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | O'neill Vincent | Sell | 2 250 | Restricted Stock Units |
| 2024-03-15 | O'neill Vincent | Buy | 2 250 | Common Stock |
| 2024-04-04 | O'neill Vincent | Sell | 165 | Common Stock |
| 2024-03-14 | O'neill Vincent | Sell | 521 | Restricted Stock Units |
| 2024-03-14 | O'neill Vincent | Buy | 521 | Common Stock |
| INSIDER POWER |
|---|
| -8.73 |
| Last 87 transactions |
| Buy: 187 774 | Sell: 228 648 |
Forecast:
16:00 - $2.77
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.77
Forecast 2: 16:00 - $2.77
Forecast 3: 16:00 - $2.77
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.75 (7.84% ) |
| Volume | 0.618 mill |
| Avg. Vol. | 1.535 mill |
| % of Avg. Vol | 40.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BTAI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $3.74 | N/A | Active |
|---|
BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Latest Press Releases
2024-04-15 08:29:50 - Press Release
Prism Marketview – Biotech Breakfast
Mobile-health network solutions (mndr) ipos; q32 bio surges; ema concludes glp-1 drugs not associated with suicidal thoughts new york, n.y., april 15, 2024 – prism marketview – healthcare equities finished lower on friday, in line with broad declines across the market.
2024-04-10 07:00:00 - Press Release
Bioxcel Therapeutics Announces Tranquility In-care Pivotal Phase 3 Trial Plan With Bxcl501 For Agitation Associated With Alzheimer's Dementia
Company plans to initiate trial following recent meeting with fda no fda-approved therapies for acute treatment of aad are currently available new haven, conn., april 10, 2024 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced details regarding the planned design of its upcoming tranquility in-care phase 3 trial to evaluate bxcl501, the company's investigational proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with alzheimer's dementia (aad) in the care setting.
2024-03-25 07:00:00 - Press Release
Bioxcel Therapeutics Announces $25 Million Registered Direct Offering
New haven, conn., march 25, 2024 (globe newswire) -- bioxcel therapeutics, inc. (the “company”) (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “shares”) of common stock, par value $0.001 per share (“common stock”), and accompanying warrants (the “accompanying warrants”) to purchase up to 3,054,609 shares of common stock at a combined offering price of $2.901 per share and accompanying warrant and pre-funded warrants (the “pre-funded warrants”) to purchase up to 5,565,027 shares of common stock and accompanying warrants to purchase up to 5,565,027 shares of common stock at a combined offering price of $2...
2024-03-15 07:00:00 - Press Release
Bioxcel Therapeutics Announces European Patent Office's Grant Of Patent For Method Of Treating Agitation In Dementia using Sublingual Dexmedetomidine
Newly granted patent aligns with company's focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501 newly granted patent aligns with company's focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501
2024-03-12 07:00:00 - Press Release
Bioxcel Therapeutics Reports Financial Results For The Fourth Quarter And Full Year 2023
Provides update on two late-stage clinical programs for bxcl501 for potential treatment of agitation recently completed meetings with u.s. food and drug administration for tranquility and serenity programs c onference call and webcast set for 8:00 a.m. et today new haven, conn.
Latest News
2024-03-07 14:52:29 - InvestorPlace
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.
2024-03-01 07:00:00 - GlobeNewsWire
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics' management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company's financial results and provide a general business update.
2024-02-09 09:05:30 - InvestorPlace
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Friday after the commercial-stage biopharmaceutical company announced a proposed underwritten public offering for its shares. This public offering includes $60 million shares of BTAI stock.
2023-11-24 06:40:00 - InvestorPlace
7 Penny Stocks With Low Floats and High Short Interest
There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.
2023-11-14 10:41:11 - Proactive Investors
BioXcel Therapeutics stock plummets as 3Q earnings fall short of expectations
BioXcel Therapeutics Inc (NASDAQ:BTAI) shares fell almost 35% after it reported a revenue miss and greater than forecast loss for the third quarter. The New Haven, Connecticut-based biopharmaceutical company reported sales of $341,000, up from $137,000 in the year-ago quarter but below estimates of $840,000.
2023-11-01 14:11:42 - PennyStocks
5 Most Active Penny Stocks Today & Why They're Moving Now
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
2023-10-31 14:18:58 - PennyStocks
Penny Stocks To Buy Today? 4 To Watch Now
Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.
2023-10-30 12:09:11 - PennyStocks
4 Penny Stocks To Watch Today With Big News, Time To Buy?
Trading penny stocks can be a risky endeavor, but having access to quality news and information can help mitigate some of that risk. As an investor or trader, it's critical to understand how news events can impact penny stocks and how to use news to your advantage when developing your trading strategy.
2023-10-26 15:06:14 - PennyStocks
3 Penny Stocks To Buy For Under $5, Are They Worth It?
Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroots.
2023-10-25 09:19:47 - PennyStocks
5 Hot Penny Stocks To Watch In The Stock Market Today
Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.